Realities of 
Retinal Disease

Significant treatment burden plays a strong role in patient outcomes and can impact vision loss. We are committed to doing more for both retina specialists and patients now and in the future.

Hero Image. Male Doctor in PPE

Vision Loss Affects Every Part of a Person’s Daily Life

Steering wheel representing how vision loss affects everyday life

Driving

Person reading a book representing how vision loss affects everyday life

Reading

Drinks clinking representing how vision loss affects everyday life

Socializing

Passport and watch representing how vision loss affects everyday life

Traveling

Couple in shape of a heart icon representing how vision loss affecting everyday life

Seeing Loved Ones

Painting palette representing how vision loss affects everyday life

Performing Hobbies

Realities of 
Retinal Disease

Significant treatment burden plays a strong role in patient outcomes and can impact vision loss. We are committed to doing more for both retina specialists and patients now and in the future.

Hero Image. Male Doctor in PPE

Vision Loss Affects Every Part of a Person’s Daily Life

Steering wheel representing how vision loss affects everyday life

Driving

Person reading a book representing how vision loss affects everyday life

Reading

Drinks clinking representing how vision loss affects everyday life

Socializing

Passport and watch representing how vision loss affects everyday life

Traveling

Couple in shape of a heart icon representing how vision loss affecting everyday life

Seeing Loved Ones

Painting palette representing how vision loss affects everyday life

Performing Hobbies

THE REALITIES OF CURRENT THERAPIES

People living with retinal diseases often refer to injection frequency as a key limitation of compliance.

These viewpoints of retina specialists are based on the 2020 Preferences and Trends Survey (PAT) from the American Society of Retina Specialists (ASRS).*

of retina specialists believe reduced treatment burden is the greatest unmet need for patients with nAMD

of retina specialists have reported long-acting and sustained delivery as the greatest unmet need for patients with nAMD

of retina specialists consider new treatment MOAs as the greatest unmet need for patients with nAMD

nAMD=neovascular age-related macular degeneration.

*1,003 retina specialists worldwide responded to this survey. The survey questions and categories were adopted by ASRS and were not influenced and/or decided upon by Genentech.

Unmet needs across Ophthalmology

Click on each disease area to learn more about patients’ specific unmet needs in each therapeutic area.

  • Requires 8-12 office visits and/or injections per year
  • Patient compliance impacts vision outcomes
  • Disease prevention

  • Requires 8-12 office visits and/or injections per year
  • Undiagnosed patients (>50%)
  • Slow progression of DR

  • No approved therapies
  • Prevention of advanced disease (nAMD)

  • Blinding disorders with no approved treatment

  • Patient adherence to current therapies

  • No currently approved treatments specifically designed for patients with Sjögren’s Disease or GVHD

  • No nonsurgical therapies

  • Requires 12 office visits and/or injections per year

DME=diabetic macular degeneration; DR=diabetic retinopathy; dry AMD=dry age-related macular degeneration; GA=geographic atrophy; GVHD=graft-versus-host disease; RVO=retinal vein occlusion.

Professor giving a lecture to students in a lab coat

Ways Genentech is helping preserve eyesight

Lightbulb icon with gear representing innovation

Patient-focused 
Innovation

Through our dedication to innovative drug discovery, biomarker research, digital therapeutics, and novel drug delivery platforms, we strive to design the right therapies for the right patients to create the best patient experience possible

Handshake icon representing collaborations with ophthalmology community

Collaborations With the Ophthalmology Community

We foster extensive collaborations with researchers, clinicians, and patient groups. We have approximately 35 ophthalmologists and retina specialists on staff at Genentech. We hire the best people to advance science and improve people’s lives

Test tubes and beakers representing breakthrough science

Breakthrough
Science

Built on the legacy of Genentech, we are pioneers developing transformative medicines that leverage cutting-edge science to address the highest unmet medical needs for patients